Clinical Scorecard: The Role of the Microbiome, Inflammation, and Immunity in Oral Squamous Cell Carcinoma: Insights into Mechanisms and Treatment Approaches

At a Glance

Key Highlights

• Oral squamous cell carcinoma accounts for approximately 90% of oral cancers.
• Chronic inflammation and dysbiosis of the oral microbiota contribute to tumorigenesis.
• Specific oral microorganisms promote carcinogenesis through various pathways.
• The microbiome-inflammation-immune axis is proposed as a conceptual framework for understanding OSCC.
• Clinical indicators such as peripheral blood inflammatory markers and salivary microbial markers are critical for diagnosis and treatment.

Guideline-Based Recommendations

Diagnosis

• Utilize peripheral blood inflammatory markers and salivary microbial markers for disease diagnosis.

Management

• Consider the role of microbiota in treatment approaches for oral squamous cell carcinoma.

Monitoring & Follow-up

• Monitor changes in inflammatory markers and microbial profiles during treatment.

Risks

• Chronic inflammation and dysbiosis may exacerbate tumor progression and immune evasion.

Patient & Prescribing Data

Individuals diagnosed with oral squamous cell carcinoma.

Therapeutic strategies may involve targeting the microbiome and inflammatory pathways.

Clinical Best Practices

• Integrate microbiome analysis into clinical assessments for OSCC.
• Address chronic inflammatory conditions such as periodontitis in patient management.

Related Resources & Content

• International Agency for Research on Cancer (IARC) 2024 Report